Electroporation delivery of DNA vaccines: prospects for success.

PubWeight™: 2.25‹?› | Rank: Top 2%

🔗 View Article (PMC 3109217)

Published in Curr Opin Immunol on April 27, 2011

Authors

Niranjan Y Sardesai1, David B Weiner

Author Affiliations

1: Inovio Pharmaceuticals, 1787 Sentry Parkway, Blue Bell, PA 19422, United States. nsardesai@inovio.com

Articles citing this

Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A (2012) 2.59

A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J (2012) 1.87

Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med (2012) 1.84

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis (2013) 1.63

Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines (2012) 1.44

Polymer multilayer tattooing for enhanced DNA vaccination. Nat Mater (2013) 1.38

DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc Natl Acad Sci U S A (2013) 1.25

Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res (2014) 1.23

HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol (2011) 1.21

Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol (2013) 1.19

The future of human DNA vaccines. J Biotechnol (2012) 1.18

Vaccines for the 21st century. EMBO Mol Med (2014) 1.17

Electrochemotherapy: technological advancements for efficient electroporation-based treatment of internal tumors. Med Biol Eng Comput (2012) 1.11

IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. Hum Vaccin Immunother (2012) 1.02

DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One (2013) 1.00

A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the α4β7-binding V2 loop of HIV gp120 in healthy volunteers. Clin Vaccine Immunol (2012) 0.93

Current trends in West Nile virus vaccine development. Expert Rev Vaccines (2014) 0.93

Elucidating the Kinetics of Expression and Immune Cell Infiltration Resulting from Plasmid Gene Delivery Enhanced by Surface Dermal Electroporation. Vaccines (Basel) (2013) 0.93

Designing vaccines for the twenty-first century society. Front Immunol (2014) 0.92

A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther (2014) 0.92

Epitope-based DNA vaccine for Alzheimer's disease: translational study in macaques. Alzheimers Dement (2013) 0.92

Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol (2012) 0.92

Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. Vaccine (2014) 0.91

Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device. Hum Gene Ther Methods (2012) 0.90

Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother (2014) 0.89

Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques. Hum Vaccin Immunother (2013) 0.89

Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) (2014) 0.89

Differential mechanisms associated with vascular disrupting action of electrochemotherapy: intravital microscopy on the level of single normal and tumor blood vessels. PLoS One (2013) 0.88

Vector Design for Improved DNA Vaccine Efficacy, Safety and Production. Vaccines (Basel) (2013) 0.88

DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother (2014) 0.87

Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes. J Virol (2014) 0.86

Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia. Hum Vaccin Immunother (2013) 0.86

Recent Developments in Preclinical DNA Vaccination. Vaccines (Basel) (2014) 0.85

Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity. Cancer Immunol Res (2013) 0.85

Non-contact helium-based plasma for delivery of DNA vaccines. Enhancement of humoral and cellular immune responses. Hum Vaccin Immunother (2012) 0.84

Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother (2013) 0.84

Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation. PLoS One (2013) 0.84

Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J Infect Dis (2014) 0.83

Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. Sci Rep (2015) 0.83

Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases. Clin Exp Vaccine Res (2015) 0.83

Electroporation mediated DNA vaccination directly to a mucosal surface results in improved immune responses. Hum Vaccin Immunother (2013) 0.82

A DNA vaccine targeting p42.3 induces protective antitumor immunity via eliciting cytotoxic CD8+T lymphocytes in a murine melanoma model. Hum Vaccin Immunother (2013) 0.82

Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239. J Virol (2014) 0.82

Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus. Hum Vaccin Immunother (2012) 0.82

In vivo molecular imaging and histological analysis of changes induced by electric pulses used for plasmid DNA electrotransfer to the skin: a study in a dorsal window chamber in mice. J Membr Biol (2012) 0.82

DNA is an efficient booster of dendritic cell-based vaccine. Hum Vaccin Immunother (2015) 0.81

HIV DNA Vaccine: Stepwise Improvements Make a Difference. Vaccines (Basel) (2014) 0.81

DNA vaccines: a simple DNA sensing matter? Hum Vaccin Immunother (2013) 0.81

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults. PLoS One (2015) 0.81

Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant. Mol Ther (2012) 0.81

Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells. Gene Ther (2014) 0.80

The secreted lipoprotein, MPT83, of Mycobacterium tuberculosis is recognized during human tuberculosis and stimulates protective immunity in mice. PLoS One (2012) 0.80

Dose-dependent inhibition of Gag cellular immunity by Env in SIV/HIV DNA vaccinated macaques. Hum Vaccin Immunother (2015) 0.80

Vaccine-Induced Simian Immunodeficiency Virus-Specific CD8+ T-Cell Responses Focused on a Single Nef Epitope Select for Escape Variants Shortly after Infection. J Virol (2015) 0.80

Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ. Vaccines (Basel) (2013) 0.79

A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines (2014) 0.79

Engineered biomaterials for development of nucleic acid vaccines. Biomater Res (2015) 0.79

DNA vaccination strategy targets epidermal dendritic cells, initiating their migration and induction of a host immune response. Mol Ther Methods Clin Dev (2014) 0.79

Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Hum Vaccin Immunother (2014) 0.79

Evaluation of the Impact of Codon Optimization and N-Linked Glycosylation on Functional Immunogenicity of Pfs25 DNA Vaccines Delivered by In Vivo Electroporation in Preclinical Studies in Mice. Clin Vaccine Immunol (2015) 0.78

Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device. Hum Gene Ther Methods (2015) 0.78

DNA vaccination by intradermal electroporation induces long-lasting immune responses in rhesus macaques. J Med Primatol (2014) 0.78

DNA vaccination for prostate cancer: key concepts and considerations. Cancer Nanotechnol (2015) 0.78

Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8(+) T Cells. J Immunol (2017) 0.78

Increased generation of HIV-1 gp120-reactive CD8+ T cells by a DNA vaccine construct encoding the chemokine CCL3. PLoS One (2014) 0.77

Electrogenetherapy of B16.F10 murine melanoma tumors with an interleukin-28 expressing DNA plasmid. Hum Vaccin Immunother (2012) 0.77

Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen. PLoS One (2015) 0.77

RNA-based vaccination: sending a strong message. Mol Ther (2013) 0.76

Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii. JCI Insight (2016) 0.76

Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors. PLoS One (2014) 0.76

Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation. Vaccines (Basel) (2013) 0.76

Spontaneous and vaccine-induced clearance of Mus musculus Papillomavirus type 1 (MmuPV1/MusPV1) infection. J Virol (2017) 0.75

Development of new plasmid DNA vaccine vectors with R1-based replicons. Microb Cell Fact (2012) 0.75

Characterization of guinea pig T cell responses elicited after EP-assisted delivery of DNA vaccines to the skin. Vaccine (2016) 0.75

DNA electroporation in rabbits as a method for generation of high-titer neutralizing antisera: examples of the botulinum toxins types A, B, and E. Hum Vaccin Immunother (2013) 0.75

A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation. Vaccine (2016) 0.75

Modulation of SIV and HIV DNA vaccine immunity by Fas-FasL signaling. Viruses (2015) 0.75

DNA vaccines encoding DEC205-targeted antigens: immunity or tolerance? Immunology (2015) 0.75

Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation. Vaccine (2016) 0.75

Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer. Alzheimers Res Ther (2017) 0.75

A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin. Hum Vaccin Immunother (2015) 0.75

Dissolving microneedles for DNA vaccination: Improving functionality via polymer characterisation and RALA complexation. Hum Vaccin Immunother (2016) 0.75

Daedalic DNA vaccination against self antigens as a treatment for chronic kidney disease. Int J Clin Exp Pathol (2013) 0.75

Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential. Viruses (2016) 0.75

Direct transfection of dendritic cells in the epidermis after plasmid delivery enhanced by surface electroporation. Hum Gene Ther Methods (2014) 0.75

DNA/MVA Vaccines for HIV/AIDS. Vaccines (Basel) (2014) 0.75

An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model. Nat Commun (2017) 0.75

Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes. Pharm Res (2017) 0.75

Rare Control of SIVmac239 Infection in a Vaccinated Rhesus Macaque. AIDS Res Hum Retroviruses (2017) 0.75

Vaccine-induced immune responses against both Gag and Env improve control of simian immunodeficiency virus replication in rectally challenged rhesus macaques. PLoS Pathog (2017) 0.75

Articles cited by this

A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34

DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature (2007) 13.56

AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature (2009) 10.83

Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 10.14

An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol (2009) 7.93

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79

Genetic immunization is a simple method for eliciting an immune response. Nature (1992) 5.30

HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature (2009) 3.86

Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1993) 3.49

Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc Natl Acad Sci U S A (2008) 3.27

Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol (2008) 2.66

Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med (2010) 2.53

Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol (2010) 2.37

DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer (2008) 2.23

Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine (2007) 1.88

Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol (2007) 1.87

Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine (2008) 1.87

Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol (2003) 1.81

Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One (2008) 1.80

A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res (2009) 1.79

Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol (2009) 1.77

Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine (2006) 1.74

In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol (1997) 1.53

Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine (2007) 1.52

In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol (2007) 1.50

Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One (2009) 1.46

A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine (2005) 1.45

Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther (2007) 1.40

Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine (2009) 1.38

Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Ther (2010) 1.35

Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine (2008) 1.34

DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther (2009) 1.34

Gene-based vaccines: recent technical and clinical advances. Trends Mol Med (2006) 1.32

Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol Ther (2010) 1.28

Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis (2011) 1.25

Real time electroporation control for accurate and safe in vivo non-viral gene therapy. Bioelectrochemistry (2006) 1.23

Biochemistry of human skin--our brain on the outside. Chem Soc Rev (2005) 1.16

Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology (2000) 1.10

Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine (2009) 1.09

Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Cancer Res (2001) 1.06

Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults. Mol Ther (2009) 1.05

Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine (2008) 1.04

A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine (2011) 1.04

Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation. Vaccine (2007) 1.03

Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One (2010) 1.01

Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation. Vaccine (2007) 1.00

Electrotransfer into skeletal muscle for protein expression. Curr Gene Ther (2006) 1.00

DNA vaccines against cancer come of age. Curr Opin Immunol (2010) 0.99

Persistent immune responses induced by a human immunodeficiency virus DNA vaccine delivered in association with electroporation in the skin of nonhuman primates. Hum Gene Ther (2009) 0.97

Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Vaccine (2009) 0.95

Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques. Clin Vaccine Immunol (2010) 0.94

Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes. Vaccine (2009) 0.92

Electroporation-based DNA transfer enhances gene expression and immune responses to DNA vaccines in cattle. Vaccine (2008) 0.91

Piezoelectric permeabilization of mammalian dermal tissue for in vivo DNA delivery leads to enhanced protein expression and increased immunogenicity. Hum Vaccin (2011) 0.90

Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation. Vaccine (2010) 0.90

Development of a highly productive and scalable plasmid DNA production platform. Biotechnol Prog (2006) 0.90

Electro-gene-transfer: a new approach for muscle gene delivery. Somat Cell Mol Genet (2002) 0.89

Immunogenicity in mice and rabbits of DNA vaccines expressing woodchuck hepatitis virus antigens. Vaccine (2008) 0.89

Massively parallel sequencing, a new method for detecting adventitious agents. Biologicals (2010) 0.88

Increased in vivo immunological potency of HB-110, a novel therapeutic HBV DNA vaccine, by electroporation. Exp Mol Med (2008) 0.88

Generation of high-titer neutralizing antibodies against botulinum toxins A, B, and E by DNA electrotransfer. Infect Immun (2009) 0.87

T for two: when helpers need help. Autoimmun Rev (2005) 0.85

Improving on the ability of endogenous hepatitis B core antigen to prime cytotoxic T lymphocytes. J Infect Dis (2010) 0.83

Enhanced in vivo transgene expression and immunogenicity from plasmid vectors following electrostimulation in rodents and primates. Vaccine (2008) 0.82

Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes. Vaccine (2009) 0.81

Synergistic effect of gene-electro transfer and adjuvant cytokines in increasing the potency of hepatitis C virus genetic vaccination. J Gene Med (2008) 0.80

DNA-based influenza vaccines: evaluating their potential to provide universal protection. IDrugs (2010) 0.80

Local temperature rises influence in vivo electroporation pore development: a numerical stratum corneum lipid phase transition model. J Biomech Eng (2007) 0.78

Articles by these authors

(truncated to the top 100)

Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40

Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 4.20

DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10

Chikungunya: a potentially emerging epidemic? PLoS Negl Trop Dis (2010) 2.05

Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol (2005) 2.01

Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine (2007) 1.88

Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine (2008) 1.87

Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One (2008) 1.80

Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol (2009) 1.77

Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood (2009) 1.75

Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol (2009) 1.68

Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine (2008) 1.67

Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 1.65

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis (2013) 1.63

Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A (2007) 1.60

Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. Hum Gene Ther (2009) 1.57

HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine (2005) 1.56

An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge. Vaccine (2012) 1.52

Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine (2007) 1.52

A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis (2011) 1.45

A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine (2005) 1.45

Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses (2005) 1.45

Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine (2007) 1.44

Anti-tumor activity mediated by protein and peptide transduction of HIV viral protein R (Vpr). Cancer Biol Ther (2009) 1.44

Molecular genetic relationship of the 3' untranslated region among Thai dengue-3 virus, Bangkok isolates, during 1973-2000. DNA Cell Biol (2009) 1.42

Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther (2007) 1.40

DNA vaccines: developing new strategies to enhance immune responses. Immunol Res (2008) 1.36

HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem (2002) 1.31

Induction of inflammation by West Nile virus capsid through the caspase-9 apoptotic pathway. Emerg Infect Dis (2002) 1.30

Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol Ther (2010) 1.28

Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine (2008) 1.28

T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS (2002) 1.27

Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis (2011) 1.25

Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One (2012) 1.25

Developing DNA vaccines that call to dendritic cells. J Clin Invest (2004) 1.24

Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res (2014) 1.23

Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur J Immunol (2008) 1.23

Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol (2008) 1.22

From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol (2006) 1.21

Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol (2013) 1.19

Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma. J Allergy Clin Immunol (2005) 1.19

DNA vaccines for HIV: challenges and opportunities. Springer Semin Immunopathol (2006) 1.18

Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine (2008) 1.16

Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism. J Virol (2008) 1.15

IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther (2010) 1.12

Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol (2011) 1.12

The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1. Nat Cell Biol (2006) 1.12

HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. Int Immunol (2004) 1.11

Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev (2004) 1.10

Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips". Vaccine (2005) 1.09

DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev (2004) 1.06

DNA vaccines: crossing a line in the sand. Introduction to special issue. Vaccine (2008) 1.06

Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther (2013) 1.05

Host cell killing by the West Nile Virus NS2B-NS3 proteolytic complex: NS3 alone is sufficient to recruit caspase-8-based apoptotic pathway. Virology (2005) 1.05

Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine (2008) 1.04

A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine (2011) 1.04

Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol (2006) 1.03

Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo. Virology (2003) 1.03

Cytokines as adjuvants for improving anti-HIV responses. AIDS (2008) 1.03

HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice. PLoS One (2013) 1.03

Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice. Curr Mol Med (2007) 1.02

HIV-1 Nef-induced FasL induction and bystander killing requires p38 MAPK activation. Blood (2005) 1.02

Mechanism of HIV-1 viral protein R-induced apoptosis. Biochem Biophys Res Commun (2003) 1.02

Suppression of HIV-1 viral replication and cellular pathogenesis by a novel p38/JNK kinase inhibitor. AIDS (2004) 1.02

Novel SIVmac DNA vaccines encoding Env, Pol and Gag consensus proteins elicit strong cellular immune responses in cynomolgus macaques. Vaccine (2009) 1.00

DNA drugs come of age. Sci Am (2010) 0.99

Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice. Vaccine (2005) 0.99

Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets. Vaccine (2011) 0.98

Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected]. Mol Ther (2011) 0.98

Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine (2008) 0.98

Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques. Vaccine (2010) 0.98

Rhesus macaques with high levels of vaccine induced IFN-gamma producing cells better control viral set-point following challenge with SIV239. Vaccine (2005) 0.98

A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge. Vaccine (2011) 0.97

DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication. Virology (2005) 0.96

Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". J Virol (2007) 0.96

High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation. Vaccine (2010) 0.95

A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques. Vaccine (2003) 0.94

Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques. Clin Vaccine Immunol (2010) 0.94

IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine. Vaccine (2008) 0.94

HIV-1 Vpr and anti-inflammatory activity. DNA Cell Biol (2004) 0.93

Parameters for DNA vaccination using adaptive constant-current electroporation in mouse and pig models. Vaccine (2008) 0.93

Interferons as potential adjuvants in prophylactic vaccines. Expert Opin Biol Ther (2010) 0.93

HIV-1 viral genes and mitochondrial apoptosis. Apoptosis (2008) 0.93

Long-term programming of antigen-specific immunity from gene expression signatures in the PBMC of rhesus macaques immunized with an SIV DNA vaccine. PLoS One (2011) 0.93

Efficient systemic expression of bioactive IL-15 in mice upon delivery of optimized DNA expression plasmids. DNA Cell Biol (2007) 0.93

Initiation of antiretroviral therapy during chronic SIV infection leads to rapid reduction in viral loads and the level of T-cell immune response. J Med Primatol (2006) 0.93

Co-immunization with an optimized plasmid-encoded immune stimulatory interleukin, high-mobility group box 1 protein, results in enhanced interferon-gamma secretion by antigen-specific CD8 T cells. Immunology (2009) 0.93

DNA vaccines for targeting bacterial infections. Expert Rev Vaccines (2010) 0.92

Ki-67 staining for determination of rhesus macaque T cell proliferative responses ex vivo. Cytometry A (2010) 0.92

Synthetic DNA vaccine strategies against persistent viral infections. Expert Rev Vaccines (2013) 0.92

VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine (2010) 0.92

Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy. Vaccine (2005) 0.92

Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes. Vaccine (2009) 0.92

Augmentation of SIV DNA vaccine-induced cellular immunity by targeting the 4-1BB costimulatory molecule. Vaccine (2008) 0.90

Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII. Vaccine (2009) 0.90

Mapping of immune responses following wild-type and mutant ABeta42 plasmid or peptide vaccination in different mouse haplotypes and HLA Class II transgenic mice. Vaccine (2005) 0.90

Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses. Hum Vaccin (2011) 0.90

Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine. Vaccine (2011) 0.90

Co-immunization with plasmid IL-12 generates a strong T-cell memory response in mice. Vaccine (2004) 0.89

Adenovirus encoding HIV-1 Vpr activates caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell lines. Oncogene (2002) 0.88